Document:

Medical Director Agreement

 Exhibit 10.9 
 MEDICAL DIRECTOR AGREEMENT 
 Agreement
(“Agreement”), made, and effective as of this,
9th day of October, 2009, by and between Cancer Genetics,
Inc. (“CGI” or the “Company”), a Delaware corporation with its principal place of business located at 201 Route 17 North, Rutherford, New Jersey 07070, and Lan Wang, M.D. (“Dr. Wang”), whose address is 14 Beechwood
Lane, Kinnelon, New Jersey 07405. 
 WITNESSETH: 

WHEREAS, CGI maintains both a commercial clinical cytogenetics and molecular laboratory (the “Laboratory” or
“Lab”), presently located at 201 Route 17 North, Rutherford, New Jersey 07070; and 
 WHEREAS, CGI’s Lab
is licensed by the States of New Jersey and New York, respectively, and accredited by both the College of American Pathologists (“CAP”), and pursuant to the Clinical Laboratory Improvement Amendments of 1988 (“CLIA”), as
administered by the State of New Jersey; and 
 WHEREAS, the Company commercially runs anatomical pathology, flow
cytometry, cytogenetic and molecular assays in its Lab, for and on behalf of clinicians, doctors, reference laboratories, and the like; and 
 WHEREAS, Dr. Wang is a licensed pathologist by the State of New Jersey and board certified in hemotology; and 
 WHEREAS, Dr. Wang is a member of CAP, and conversant with CLIA and CAP regulations; and 
 WHEREAS, the Company requires a licensed Medical Director (“Medical Director”) to oversee its Lab and is desirous of retaining Dr. Wang to both supervise and monitor the Lab and
assist with the Company’s accreditation by CAP, CLIA, and the states of New Jersey and New York, and to maximize the commercial viability of the Lab; and 
 NOW, THERFORE, the Parties hereto agree as follows: 
 1.
DUTIES: In return for the compensation stated herein, below, Dr. Wang shall be retained as Medical Director and perform, and be responsible for, the following duties: 

 

	 	a)	Where required by the Company, and necessary for the maximum utilization of applicable CPT and ICD-9 codes, sign out all cases (“Reports”) within twenty-four
(24) hours of completion and presentation to Dr. Wang, where deemed necessary to either have such Reports signed by a licensed medical doctor or for maximum reimbursement; 

	 	b)	If the Company’s case volume increases to a point where it exceeds the agreed upon hours stated below, the Medical Director will insure that appropriate coverage
is afforded the Company, and in place. 

  

	 	i.	Should the foregoing occur, the parties shall re-visit the issue of remuneration to arrive at reasonable compensation for the additional responsibilities hereunder.

  

	 	c)	All sign outs done at CGI by Medical Director shall be done in CGI’s name, and on its behalf, whether a professional or technical component;

  

	 	d)	Oversee, and supervise the Company’s Lab in ensuring that the Lab is and remains CLIA, New York State, and CAP compliant; 

 

	 	e)	Oversee, and supervise the Company’s laboratory directors assisting the Company to maintain standard operating procedure (“SOP”) manuals for both CAP and
CLIA, and the States of New York and New Jersey, and if required by Maryland, Florida and California; 

  

	 	f)	Be available for conferences, meetings, and consultations on a reasonable, but “as needed” basis and physically available for any inspections by CLIA, New
York State, CAP, etc.; 

  

	 	g)	Medical Director, or her designee shall be required to spend fifteen (15) hours weekly, and to “sign-off” timely on all Reports either remotely, through
use of a Company computer, and/or pathology website, or while physically on premises; 

  

	 	h)	Conduct two (2), twice-yearly Lab meetings to review SOP’s and Lab procedures with the Lab staff. 

It is expected that Medical Director, or her designee, will not be required to expend more than fifteen (15) hours, total, each week
in the performance of the required duties hereunder. 
  

	 	2.	TERM: The term of this Agreement (“Term”) shall be for one (1) year from the Effective Date, and shall renew automatically, unless
terminated by either party, in writing, within ninety (90) days of the end of the Term. 

  

	 	a)	 The Medical Director recognizes that the Company may be irreparably harmed, causing damage which would be difficult if not impossible to ascertain, and
likely incapable of being remedied by money, should Medical Director resign his position before the end of the term without providing the Company the ninety (90) day notice required herein, and deemed necessary by the Company to reasonably
arrange for a replacement. Therefore, Medical Director agrees that, in addition to other appropriate relief, and without limiting any other remedy available to the Company, the Company shall be entitled to injunctive relief, without the posting of a
bond, to maintain the “status quo” until such time as the 

	 	
Company reasonably can replace the Medical Director, should the Medical Director fail to provide the requisite notice. 

 

	 	b)	The ninety (90) day requirement shall not be deemed applicable, if it is ultimately determined that the Company was in breach of a material term of this Agreement,
and had not cured that breach within (20) days of being notified, in writing, by Medical Director, as to said alleged breach. 

  

	 	3.	COMPENSATION: In return for the duties to be performed hereunder, the Company shall pay the Medical Director, Two Hundred Twenty-Five Thousand ($225,000)
Dollars, per annum, payable monthly in increments of Eighteen Thousand, Seven Hundred and Fifty ($18,750.00) Dollars within fifteen (15) days of the close of the preceding month. 

 

	 	a)	Twice yearly, the parties shall meet to discuss, and adjust if necessary, the compensation hereunder, dependent upon the volume of work, and the necessary time to be
devoted to overseeing and directing the Labs. 

  

	 	b)	Provided that this Agreement is extended past its initial Term, the Medical Director shall be eligible to receive options (“Options”), as recommended by the
Company’s President and Chief Executive Officer (“CEO”), and as approved by the Company’s Board of Directors, pursuant to the Company’s Stock Option Plan (“SOP”), as revised by year-end, 2009, and its bylaws.

  

	 	c)	Medical Director shall be entitled to a bonus in the discretion of the Board of Directors, commensurate with the Company’s standard policies.

  

	 	4.	APPLICABLE LAW: This Agreement shall be governed, construed, and enforced by the laws of the State of New Jersey, and the parties agree to submit to any
court of competent jurisdiction in the State of New Jersey. 

  

	 	5.	NOTICES: All notices required or permitted by this Agreement shall be in writing and shall be delivered by U.S. certified mail, return receipt requested,
with postage prepaid, or by commercial messenger service with proof of delivery. Notices to the Company shall be delivered to its principal office or by personal delivery to both its Managers. Notice to the Medical Director shall be delivered to the
Medical Director at his residence or principal place of employment. 

 Any notices required hereunder shall be sent
as follows: 
  

					
	 To Company:

Louis J. Maione

Cancer Genetics, Inc.

201 Route 17 North

Rutherford, New Jersey 07070
	  	To Medical Director:
 Lan Wang, M.D.

14 Beechwood Lane

Kinnelon, New Jersey 07405
	  	

  

	 	6.	 ENTIRE AGREEMENT: This document embodies the entire Agreement between the Company and the Medical Director as to the relationship of the
parties, and supersedes all 

	 	
prior or contemporaneous written or oral discussions, understandings, representations, or negotiations as to subject matter and, except as otherwise expressly provided herein, this Agreement
shall not be affected by reference to any other document. 

  

	 	7.	ENFORCEABILITY: The Medical Director hereby agrees that if any provision of this Agreement is held invalid or unenforceable by any court of competent
jurisdiction, such provision shall be severed and the balance of this Agreement shall remain valid and enforceable and, further, that should any Court hold that the scope of business restricted or the time or geographical limitations of the
covenants and agreements contained herein are too broad to be enforced, such court shall not disregard those provisions, but shall enforce such provisions as to such scope, time, and geographical area as the Court deems equitable.

  

	 	8.	HEIRS AND ASSIGNS: This Agreement shall be binding upon inure to the benefit of the parties hereto, their successor and assigns. This Agreement may not be
assigned by the Medical Director without the written consent of the Company. The Company may assign any part or all of this Agreement in its sole discretion. 

 

	 	9.	NECESSARY ACTS: The parties shall execute such other documents and take such acts, as may be necessary and desirable for the implementation and
consummation of this Agreement. 

  

	 	10.	WAIVER, MODIFICATIONS, AND AMENDMENTS: The terms, provisions, and conditions of this Agreement may not be altered, modified, changed or otherwise amended
unless by a written instrument signed by Medical Director and by the Company. Any waiver of breach or change as to any provision, covenants or warranty contained in this Agreement much be in writing and signed by the Medical Director and by the
Company, and shall not alter the obligations of the parties as to any other provision, covenant or warranty contained herein. 

  

	 	11.	COUNTERPARTS: This Agreement may be signed in any number of counterparts with the same effect as if the signature of each such counterpart were upon the
same instrument. 

  

							
	Dated:	 		 	Medical Director
			
	Oct. 7, 2009	 		 	 /s/    Lan Wang, M.D.

			
	Dated:	 		 	Cancer Genetics, Inc.
				
	 October 2, 2009
	 		 	By:	 	 /s/    Louis J. Maione

		 		 		 	Louis J. MaioneEmployment Agreement between Cancer Genetics, Inc. and Louis J. Maione

 Exhibit 10.10 
 EMPLOYMENT AGREEMENT 
 THIS EMPLOYMENT AGREEMENT
(this “Agreement”), dated as of this 21st day of
October, 2009, by and between Cancer Genetics, Inc., a Delaware corporation (the “Company”), and Louis J. Maione (the “Employee”). The Company and the Employee shall sometimes be referred to herein individually, as a
“Party” and collectively, as the “Parties.” 
 WITNESSETH: 

WHEREAS, the Company is in the businesses of (i) designing and manufacturing genomic based reagents for the diagnosis
and prognosis of cancer and, (ii) operating a service lab for esoteric testing of cancer; 
 WHEREAS, the
Employee has been providing on-going services to the Company as chief executive officer; 
 WHEREAS, the Company
believes that the Employee’s skills are beneficial to the Company; and 
 WHEREAS, the Company desires to
continue to employ the Employee as general counsel and as Director of the Company’s European operations. 
 NOW,
THEREFORE, in consideration of the mutual covenants and the premises herein set forth, the Company and the Employee hereby agree as follows: 
 1. Employment. The Company hereby employs the Employee, and the Employee hereby accepts employment, under the terms and conditions set forth in this Agreement. 

2. Term. The term of this Agreement shall commence as of the date of this Agreement and shall continue for a period of two
(2) years (the “Initial Term”). This Agreement may be renewed upon mutual consent of the Parties for additional one (1) year periods after the expiration of the Initial Term. The Initial Term, together with any renewal periods,
shall sometimes collectively be referred to herein as the “Term.” 
 3. Position and Duties. The Employee shall
have the position of general counsel, subject to reconfirmation by the board of directors of the Company (the “Board of Directors”), and shall have the duties and responsibilities of that office, as well as such other duties and
responsibilities as the Chairman and/or Chief Executive Officer may from time-to-time reasonably direct. Specifically, Employee will report to the Chairman with respect to all European operations and to the CEO (once the position is filled) for all
general counsel and other matters. Until the CEO position is filled, the Employee shall report to the Chairman with respect to such general counsel responsibilities. 
 4. Obligations of Employee. The Employee shall devote the Employee’s services to the Company and perform the Employee’s duties faithfully and to the best of the Employee’s ability.
The Employee shall devote all of the Employee’s working time, attention and efforts to the business 

 
and affairs of the Company; provided, however, that the Employee shall be free to engage in outside activities that do not interfere with the performance of the Employee’s
duties under this Agreement and are not in conflict with the interests of the Company. 
 5. Salary and Benefits. In
consideration of the Employee’s agreement to be employed by the Company and for the services to be rendered under this Agreement, the Company agrees to provide compensation to the Employee as follows: 

(a) Salary. During the Term, the Employee shall be paid an annual salary of Two Hundred Fifty Thousand Dollars ($250,000.00)
payable in equal biweekly installments. The annual salary of the Employee shall be reviewed on an annual basis by the Board of Directors, in its sole discretion, taking into consideration, among other things, the salary and compensation of other
officers of the Company hired after the date of this Agreement, and such other factors as the Board of Directors deems relevant. 
 (b) Bonus. The Employee shall be eligible for an annual bonus equal to up to twenty percent (20%) of the Employee’s then current annual salary. The Company agrees that within sixty
(60) days of this Agreement, the Company and the Employee shall develop reasonable financial and performance benchmarks or milestones, (collectively “Milestones”) with respect to the European operations. The Employee shall be entitled
to an annual bonus in accordance with the Milestones. 
 (c) Reimbursement of Expenses. During the Term, the Company
shall reimburse the Employee for the Employee’s reasonable business expenses incurred in the performance of the Employee’s duties under this Agreement; provided, however, that such expenses are verified by written receipts or
invoices if and to the extent required by the Board of Directors. 
 (d) Fringe Benefits. The Employee shall be eligible
to participate in any medical plans and other similar benefits, now or hereafter available to employees of the Company, subject only to the Employee’s meeting the qualification requirements for such benefits. During the Term, the Employee shall
be entitled to receive vacation in accordance with the written policy of the Company, as prescribed by the Board of Directors from time-to-time. In addition, the Employee shall continue to receive an automobile lease allowance of up to Five Hundred
Fifty Dollars ($550.00) per month throughout the Term. 
 (e) Stock Options. The Employee will be entitled to participate
in a stock option plan of the Company, as approved by the Board of Directors (the “Stock Option Plan”), subject only to the Employee’s meeting the qualification requirements for the Stock Option Plan. The number of options to be
granted to the Employee pursuant to the Stock Option Plan, if any, and the purchase price for such options, shall be determined by the Board of Directors, in its sole and absolute discretion, from time to time. 

6. Termination. 
 (a) This Agreement shall terminate and the Employee shall cease to be an employee of the Company upon occurrence of any of the following events: 

(i) The mutual agreement of the Employee and the Company; 

 (ii) Death of the Employee; 

(iii) The Employee’s employment being terminated for “cause”, For purposes of this Agreement, the term “cause”
shall mean any one of the following acts: 
 (A) The Employee’s fraud, dishonesty or gross misfeasance, as determined by
the Board of Directors; 
 (B) The Employee’s conviction by a court of competent jurisdiction of a crime involving moral
turpitude or dishonesty; or 
 (C) The Employee’s (1) unreasonable failure to perform his duties, as determined by
the Board of Directors, or (2) substantial and material breach of, or default under, this Agreement or the Proprietary Information and Invention Assignment Agreement (as defined herein). The unreasonable failure of the Company, as determined by
the Board of Directors, to meet reasonable sales and product development benchmarks, as may be agreed to from time to time by the Employee and the Board of Directions. In the case of any of the conditions set forth in this Section 6(a)(iii)(C),
the Employee shall be given written notice of the intent of the Board of Directors to terminate the Employee’s employment under this paragraph and shall set forth in such notice the reasons for the Company’s intention to terminate pursuant
to this paragraph, and provided that the Employee shall be permitted ninety (90) days from receipt of such written notice to cure any such breach or default to the reasonable satisfaction of the Board of Directors. 

(iv) Disability of the Employee. For the purpose of this Agreement, the Employee shall be deemed to have become disabled when the Board
of Directors, upon the advice of a qualified physician, shall have determined that the Employee has become physically or mentally incapable (excluding infrequent and temporary absences due to ordinary illness) of performing his duties under this
Agreement. Before making any termination decision pursuant to this Section 6(a)(iv), the Board of Directors shall determine whether there is any reasonable accommodation (within the meaning of the Americans With Disabilities Act) which would
enable the Employee to perform the essential functions of the Employee’s position under this Agreement despite the existence of such disability. If such a reasonable accommodation is possible, the Company shall make that accommodation and shall
not terminate the Employee’s employment hereunder based on such disability; 
 (v) The cessation of the business of the
Company. 
 (b) This Agreement may be terminated by the Employee, in which case the Employee shall cease to be an employee of
the Company, upon (i) the Company’s breach of any of the terms and conditions required to be complied with by the Company pursuant to this Agreement, or (ii) an unreasonable and material change in the Employee’s title, duties or
responsibilities by the Board of Directors; provided, however, that prior to terminating this Agreement, the Company shall be given written notice of the intent of the Employee to terminate the Employee’s employment under this
paragraph the Company shall be permitted ninety (90) days from receipt of such written notice to cure any such breach or default to the reasonable satisfaction of the Employee. Notwithstanding

 
any provision of this Agreement to the contrary, this Agreement may not be terminated by the Employee pursuant to this Section 6(b) as a result of a reduction of the level of compensation
paid or provided to the Employee pursuant to Section 5, so long as such reduction is applied to all other employees of the Company having similar seniority and/or responsibility. 

(c) This Agreement may be terminated by the Company at any time without “cause” (as defined in Section 6(a)) upon thirty
(30) days’ prior written notice to the Employee. Upon any such termination of this Agreement, all obligations of the Company under this Agreement shall thereupon immediately terminate other than any obligations with respect to earned but
unpaid compensation and bonus and unreimbursed expenses under Section 5, obligations with respect to Severance Payments (as defined in Section 7) and the obligations of the Company pursuant to Sections 14 and 15. 

7. Payments upon Termination. If this Agreement is terminated pursuant to Section 6(b) or 6(c), and subject to the
Employee’s signing a general release of claims in a form and manner satisfactory to the Company, the Employee shall be entitled to receive accrued benefits and twelve (12) months salary at the Employee’s then current rate of annual
salary, together with continuation of health insurance benefits for a period of twelve (12) months from the date of termination (the “Severance Payment”). The Severance Payment shall be paid in equal bi-weekly installments over the
relevant severance period. Notwithstanding the foregoing, the Company may elect to pay the Employee a single lump sum payment, in which case, the Company shall be entitled to discount to its present value, the sum payable under this paragraph, on
the basis of the applicable prime rate of interest as advertised in the Wall Street Journal, Eastern Edition, on the date of termination of this Agreement. The Employee specifically agrees that, upon termination pursuant to Section 6(b)
or 6(c), the Company will not have any obligation with respect to the unearned (future) compensation and bonus under Section 5 for the remaining Term, if any, under this Agreement. 

8. Insurance on Employee. The Company shall be entitled to obtain and maintain, at the Company’s expense, key person life
insurance on the life of the Employee, naming the Company as the beneficiary of such policy. The Employee agrees to cooperate with the Company and take all reasonable actions necessary to obtain such insurance, such as taking usual and customary
physical examinations and providing true and accurate personal, health related information for any application at no cost to the Employee. 
 9. Proprietary Information and Invention Assignment Agreement. The terms of the proprietary information and invention assignment agreement dated October 21, 2007 attached hereto as Exhibit A (the
“Proprietary Information and Invention Assignment Agreement”) are incorporated herein by reference and remain in full force and effect. If there is any conflict between the terms of the Proprietary Information and Invention Assignment
Agreement and the terms of this Agreement, the terms of this Agreement shall prevail. 
 10. Assignment. This Agreement
is personal to each of the Parties, and neither Party may assign nor delegate any of that Party’s rights or obligations under this Agreement without first obtaining the written consent of the other Party, except that the Company may assign and
delegate its rights and obligations under this Agreement to a legal successor to the Company or an assignee whose management and ownership remains unchanged from that of the Company. 

 11. Notices. All notices required under this Agreement shall be given by personal
delivery or by mailing, via certified or registered mail, return receipt requested, addressed to the Company or to the Employee and addressed as follows: 
  

			
	To the Company:	  	
		  	 Cancer Genetics, Inc.
 201
Route 17 North, 2nd Floor

Rutherford, New Jersey 07070
 Attn:
President

		
	To Employee:	  	
		  	 Louis J. Maione
 850 Park
Avenue, 10B
 New York, New York 10075

 If sent by mail, such notice shall be deemed to have been given on the date set forth on receipt of the registered or
certified mail or upon the third day after mailing, whichever is earlier. Addresses may be changed only by giving written notice thereof, via registered or certified mail, to the other Party. 

12. Expenses of Enforcement. In the event that any suit or legal proceeding is brought to enforce any provision of this Agreement,
the prevailing Party in such suit or proceeding shall be entitled to receive all of such Party’s reasonable expenses, including attorneys’ fees and costs. 
 13. Prior Agreement. The Parties agree that this Agreement amends and supersedes the terms of that certain employment agreement between the parties dated October 2, 2007 (the “2007
Agreement”). The Parties agree that this Agreement is entered into voluntarily, and the Employee waives and releases the Company and its officers, directors, shareholders, agents, and consultants from any and all claims, which the Employee had
or now has in relation to the 2007 Agreement (including demand for the Severance Payment thereunder). 
 14. Registration
Rights. The Company agrees that if the Company proposes to file a registration statement under the Securities Act with respect to any equity security (including a registration statement on Form S-4 or S-8 or any successor or similar forms), the
Company shall include in such registration statement, and shall use its best efforts to cause the managing underwriter, if any, of any such proposed offering to permit the offering in such registration statement of, the shares of Common Stock of the
Company owned by the Employee, on the terms and conditions most favorably provided with respect to any of the other equity securities included in such registration statement. The provisions to this Section shall survive the expiration or termination
of this Agreement. 
 15. Loan Repayment. Within ninety (90) days, of the closing of $3,500,000 or more of the
Company’s Series B Preferred Stock offering, the Company shall pay in full the principal and all accrued and unpaid interest to the date of repayment due and payable pursuant to the Company’s Convertible Promissory Note 1 dated
December 27, 2006 (the “Note”). Notwithstanding the foregoing, the Note, and all accrued interest, shall be paid by the Company upon the expiration or earlier termination for any reason, of this Agreement. 

 16. Miscellaneous. 

(a) This Agreement shall be governed by and construed exclusively in accordance with the laws of the State of New Jersey without giving
effect to any choice or conflict of law rules to the contrary. 
 (b) Should any provision of this Agreement be held invalid or
unenforceable, the remainder of this Agreement shall not be affected and shall be enforceable to the fullest extent permitted at law or in equity. 
 (c) This Agreement contains the entire agreement between the Parties concerning the subject matter hereof and supersedes all prior conversations, proposals, negotiations, understandings, and agreements,
whether written or oral concerning the subject matter hereof. 
 (d) This Agreement shall not be amended, altered, changed,
modified, supplemented, or rescinded in any manner except by written agreement executed by both Parties expressly referring to this Agreement. 
 (e) Any one or more waivers of a breach of a covenant or condition by either Party shall not be construed as a waiver of a subsequent breach of the same covenant or condition. 

(f) The rights and obligations under this Agreement shall survive the termination of the Employee’s service to the Company in any
capacity and shall be binding upon the Employee and the successors and assigns of the Company. 
 [Signature Page to Follow]

 IN WITNESS WHEREOF, each Party has executed, or caused to be executed by a duly
authorized individual, this Agreement as of the date first set forth above. 
  

			
		 	CANCER GENETICS, INC.
		
	By:	 	 /s/ Raju S.K. Chaganti

	Name:	 	Raju S.K. Chaganti
	Title:	 	Chairman
		
		 	EMPLOYEE
		
		 	 /s/ Louis J. Maione

		 	Louis J. Maione

 EXHIBIT A 
 PROPRIETARY INFORMATION AND 
 INVENTION ASSIGNMENT AGREEMENT

 PROPRIETARY INFORMATION AND 

INVENTION ASSIGNMENT AGREEMENT 
 THIS PROPRIETARY INFORMATION AND INVENTION ASSIGNMENT AGREEMENT (this “Agreement”), dated as of this 21 day of October, 2007, by and between Cancer Genetics, Inc., a Delaware corporation
(the “Company”), and Louis J. Maione (the “Inventor”). The Company and the Inventor shall sometimes be referred to individually, as a “Party” and collectively, as the “Parties.” 

WITNESSETH: 
 WHEREAS, the Inventor maintains a relationship with the Company in a capacity in which the Inventor has received or contributed, or may receive or contribute, to the Company’s proprietary or
confidential information; and 
 WHEREAS, the Company develops and uses valuable technical and non-technical confidential
and proprietary information which it may wish to commercialize and protect either by patents, trademarks, copyrights, or by keeping secret and confidential. 
 NOW, THEREFORE, in consideration of the execution by the Company of that certain employment agreement, by and between the Company and the Inventor, of even date herewith, the receipt and
sufficiency of which hereby acknowledged, the Company and Inventor, intending to be legally bound, hereby agree as follows: 

1. Employment Relationship: Termination of Prior Agreement. The Inventor understands and acknowledges that this Agreement does not
alter, amend or expand upon any rights the Inventor may have to continue in the employ of or the duration of such employment by the Company under any existing agreements, by and between the Company and the Inventor or under applicable law. Any
employment relationship between the Company and the Inventor, whether commenced prior to or upon the date of this Agreement, shall be referred to herein as the “Relationship.” 

2. Proprietary Information. 
 (a) Company Information. The Inventor agrees at all times during the term of the Relationship with the Company and thereafter, to hold in strictest confidence, and not to use, except for the
benefit of the Company to the extent necessary to perform the Inventor’s obligations to the Company under the Relationship, or to disclose to any person, firm, corporation or other entity without written authorization of the board of directors
of the Company, any Proprietary Information (as defined herein) of the Company which the Inventor obtains or creates. The Inventor further agrees not to make copies of such Proprietary Information except as authorized by the Company. The Inventor
understands that “Proprietary Information” means any Company proprietary information, technical data, trade secrets or know-how, including, but not limited to, research, product plans, products, services, suppliers, customer lists and
customers (including, but not limited to, customers of the Company on whom the Inventor called or with whom the Inventor became acquainted during the Relationship), prices and costs, markets, software, developments, inventions, laboratory notebooks,
processes, formulas, technology, designs, drawings, engineering, hardware configuration information, marketing, licenses, finances, budgets or other business information disclosed to the Inventor by the Company either directly or indirectly in
writing, orally or by 

 
drawings or observation of parts or equipment or created by the Inventor during the period of the Relationship, whether or not during working hours. The Inventor understands that
“Proprietary Information” includes, but is not limited to, information pertaining to any aspects of the Company’s business which is either information not known by actual or potential competitors of the Company or other third parties
not under confidentiality obligations to the Company, or is otherwise proprietary information of the Company or its customers or suppliers, whether of a technical nature or otherwise. The Inventor further understands that “Proprietary
Information” does not include any of the foregoing items, which have become publicly and widely known and made generally available through no wrongful act of the Inventor or of others who were under confidentiality obligations as to the item or
items involved. 
 (b) Prior Obligations. The Inventor represents that the Inventor’s performance of all terms of
this Agreement as an employee of the Company has not breached and will not breach any agreement to keep in confidence proprietary information, knowledge or data acquired by the Inventor prior or subsequent to the commencement of the Relationship
with the Company, and the Inventor will not disclose to the Company or use any inventions, confidential or non-public proprietary information or material belonging to any previous client, employer or any other party. The Inventor will not induce the
Company to use any inventions, confidential or non-public proprietary information, or material belonging to any previous client, employer or any other party. 
 (c) Third Party Information. The Inventor recognizes that the Company has received and in the future will receive confidential or proprietary information from third parties subject to a duty on the
Company’s part to maintain the confidentiality of such information and to use it only for certain limited purposes. The Inventor agrees to hold all such confidential or proprietary information in the strictest confidence and not to disclose it
to any person, firm or corporation or to use it except as necessary in carrying out the Inventor’s work for the Company consistent with the Company’s agreement with such third party. 

3. Inventions. 
 (a) Inventions Retained and Licensed. The Inventor has attached hereto, as Exhibit A, a list describing with particularity all inventions, original works of authorship, developments, improvements,
and trade secrets which were made by the Inventor prior to the commencement of the Relationship (collectively referred to as “Prior Inventions”), which belong solely to the Inventor or belong to the Inventor jointly with another, which
relate in any way to any of the Company’s proposed businesses, products or research and development, and which are not assigned to the Company hereunder; or, if no such list is attached, the Inventor represents that there are no such Prior
Inventions. If, in the course of the Relationship with the Company, the Inventor incorporates into a Company product, process or machine a Prior Invention owned by the Inventor or in which the Inventor has an interest, the Company is hereby granted
and shall have a non-exclusive, royalty-free, irrevocable, perpetual, worldwide license (with the right to sublicense) to make, have made, copy, modify, make derivative works of, use, sell and otherwise distribute such Prior Invention as part of or
in connection with such product, process or machine. 
 (b) Assignment of Inventions. The Inventor agrees that the
Inventor will promptly make full written disclosure to the Company, will hold in trust for the sole right and benefit of the Company, and hereby assign to the Company, or its designee, all of the Inventor’s right, title and interest throughout
the world in and to any and all inventions, original works of authorship, developments, concepts, know-how, improvements or trade secrets, whether or not patentable or 

 
registrable under copyright or similar laws, which the Inventor may solely or jointly conceive or develop or reduce to practice, or cause to be conceived or developed or reduced to practice,
during the period of time in which the Inventor is employed by the Company (collectively referred to as “Inventions”), except as provided in Section 3(e) below. The Inventor further acknowledges that all inventions, original works of
authorship, developments, concepts, know-how, improvements or trade secrets which are made by the Inventor (solely or jointly with others) within the scope of and during the period of the Inventor’s Relationship with the Company are “works
made for hire” (to the greatest extent permitted by applicable law) and are compensated by the Inventor’s salary, unless regulated otherwise by applicable law. 
 (c) Maintenance of Records. The Inventor agrees to keep and maintain adequate and current written records of all Inventions made by the Inventor (solely or jointly with others) during the term of
the Relationship with the Company. The records may be in the form of notes, sketches, drawings, flow charts, electronic data or recordings, laboratory notebooks, and any other format. The records will be available to and remain the sole property of
the Company at all times. The Inventor agrees not to remove such records from the Company’s place of business except as expressly permitted by Company policy which may, from time to time, be revised at the sole election of the Company for the
purpose of furthering, the Company’s business. The Inventor agrees to return all such records (including any copies thereof) to the Company at the time of termination of the Relationship with the Company as provided for in Section 4.

 (d) Patent and Copyright Rights. The Inventor agrees to assist the Company, or its designee, at the Company’s
expense, in every proper way to secure the Company’s rights in the Inventions and any copyrights, patents, trademarks, mass work rights, moral rights, or other intellectual property rights relating thereto in any and all countries, including
the disclosure to the Company of all pertinent information and data with respect thereto, the execution of all applications, specifications, oaths, assignments, recordations, and all other instruments which the Company shall deem necessary in order
to apply for, obtain, maintain and transfer such rights and in order to assign and convey to the Company, its successors, assigns and nominees the sole and exclusive rights, title and interest in and to such Inventions, and any copyrights, patents,
mask work rights or other intellectual property rights relating thereto. The Inventor further agrees that the Inventor’s obligation to execute or cause to be executed, when it is in the Inventor’s power to do so, any such instrument or
papers shall continue after the termination of this Agreement until the expiration of the last such intellectual property right to expire in any country of the world. If the Company is unable because of the Inventor’s mental or physical
incapacity or unavailability or for any other reason to secure the Inventor’s signature to apply for or to pursue any application for any United States or foreign patents, copyright, mask works or other registrations covering Inventions or
original works of authorship assigned to the Company as above, then the Inventor hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as the Inventor’s agent and attorney in fact, to act for and in
the Inventor’s behalf and stead to execute and file any such applications and to do all other lawfully permitted acts to further the application for, prosecution, issuance, maintenance or transfer of letters patent, copyright or other
registrations thereon with the same legal force and effect as if originally executed by the Inventor. The Inventor hereby waives and irrevocably quitclaims to the Company any and all claims, of any nature whatsoever, which the Inventor now or
hereafter have for infringement of any and all proprietary rights assigned to the Company. 
 (e) Exception to
Assignments. The Inventor understands that the provisions of this Agreement requiring assignment of Inventions to the Company do not apply to any inventions for which no equipment, supplies, facility or trade secret information of the Company
was used and 

 
which was developed entirely on the Inventor’s own time, unless (a) the Inventions relate (i) directly to the business of the Company, or (ii) to the Company’s actual or
demonstrably anticipated research or development, or (b) the Inventions result from any work performed by the Inventor for the Company. The Inventor will advise the Company promptly in writing of any inventions that the Inventor believes meet
such provisions and are not otherwise disclosed on Exhibit A. 
 4. Returning Company Documents. The Inventor agrees
that, at the time of termination of the Inventor’s Relationship with the Company, the Inventor will deliver to the Company (and will not keep in the Inventor’s possession, recreate or deliver to anyone else) any and all Proprietary
Information and any and all devices, records, data, notes, reports, proposals, lists, correspondence, specifications, drawings, blueprints, sketches, laboratory notebooks, materials, flow charts, equipment, other documents or property, or
reproductions of any of the aforementioned items developed by the Inventor pursuant to the Relationship or otherwise belonging to the Company, its successors or assigns. The Inventor further agrees that any property situated on the Company’s
premises and owned by the Company, including disks and other storage media, filing cabinets or other work areas, is subject to inspection by Company personnel at any time with or without notice. In the event of the termination of the Relationship,
the Inventor agrees to sign and deliver the “Termination Certification” attached hereto as Exhibit B. 
 5.
Notification to Other Parties. 
 (a) Employees. In the event that the Inventor leaves the employ of the Company,
the Inventor hereby consents to notification by the Company to the Inventor’s new employer about the Inventor’s rights and obligations under this Agreement. 
 (b) Consultants. The Inventor hereby grants consent to notification by the Company to any other parties besides the Company with whom the Inventor maintains a consulting relationship, including
parties with whom such relationship commences after the effective date of this Agreement, about the Inventor’s rights and obligations under this Agreement. 
 6. Solicitation of Employees, Consultants and Other Parties. The Inventor agrees that during the term of the Inventor’s Relationship with the Company, and for a period of twelve
(12) months immediately following the termination of the Inventor’s Relationship with the Company for any reason, whether with or without cause, the Inventor shall not either directly or indirectly solicit, induce, recruit or encourage any
of the Company’s employees or consultants to terminate their relationship with the Company, or take away, hire or otherwise engage the services of such employees or consultants, or attempt to solicit, induce, recruit, encourage or take away,
employees or consultants of the Company, either for the Inventor or for any other person or entity. Further, for a period of twelve (12) months following termination of the Inventor’s Relationship with the Company for any reason, whether
with or without cause, the Inventor shall not solicit any licensor to or customer of the Company or licensee of the Company’s products, in each case, that are known to the Employee, with respect to any business, products or services that are
competitive to the products or services offered by the Company or under development as of the date of termination of the Inventor’s Relationship with the Company. 
 7. Noncompetition. During the term of the Inventor’s Relationship with the Company and for twelve (12) months following the termination of the Inventor’s Relationship for any reason,
whether with or without cause, the Inventor will not, without the Company’s prior written consent, directly or indirectly work on any products or services that are competitive with products or services

 
(a) which were being commercially developed or exploited by the Company during the term of the Inventor’s Relationship with the Company, and/or (b) on which the Inventor worked or about
which the Inventor learned Proprietary Information during the term of the Inventor’s Relationship. 
 8. Representations
and Covenants. 
 (a) Facilitation of Agreement. The Inventor agrees to execute promptly any proper oath or verify
any proper document required to carry out the terms of this Agreement upon the Company’s written request to do so. 
 (b)
Conflicts. The Inventor represents that the Inventor’s performance of all the terms of this Agreement does not and will not breach any agreement that the Inventor has entered into, or will enter into with any third party, including
without limitation any agreement to keep in confidence proprietary information acquired by the Inventor in confidence or in trust prior to commencement of the Inventor’s Relationship with the Company. 

(c) Voluntary Execution. The Inventor certifies and acknowledges that the inventor has carefully read all of the provisions of
this Agreement and that the Inventor understands and will fully and faithfully comply with such provisions. 
 9, General
Provisions. 
 (a) Governing Law. The validity, interpretation, construction and performance of this Agreement shall
be governed by the laws of the State of New Jersey, without giving effect to either the principles of conflict of laws or to the “draftsman” presumption. 
 (b) Entire Agreement. This Agreement sets forth the entire agreement and understanding between the Parties relating to the subject matter herein and merges all prior discussions between the
Parties. No modification or amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective unless in writing signed by the Parties. Any subsequent change or changes in the Inventor’s duties, obligations,
rights or compensation will not affect the validity or scope of this Agreement. 
 (c) Severability. If any provision of
this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect without such provision, and this Agreement shall be construed to the fullest
extent possible so as to give effect to the intentions of the provision found to be unenforceable or invalid. 
 (d)
Successors and Assigns. This Agreement will be binding upon the Inventor’s heirs, executors, administrators and other legal representatives, and the Inventor’s successors and assigns, and will be for the benefit of the Company, its
successors, and its assigns. 
 (e) Survival. The provisions of this Agreement shall survive the termination of the
Relationship and the assignment of this Agreement by the Company to any successor in interest or other assignee. 
 (f)
Injunctive Relief. The Inventor acknowledges that should the Inventor violate the provisions of this Agreement, it will be difficult or impossible to determine the resulting damage to the Company. Therefore, in the event of the
Inventor’s breach of the provisions of this 

 
Agreement, in addition to any other remedies it may have, the Company shall be entitled to temporary and permanent injunctive relief to enforce the provisions of this agreement without the
necessity of proving actual damage. 
 (g) Attorneys’ Fees. The Inventor agrees that the Inventor will be liable for
all costs or expenses, including, but not limited to, attorneys’ fees, that the Company may incur in enforcing the provisions of this agreement, regardless of whether litigation is actually commenced to enforce the provisions of this Agreement.
The Company’s right to costs or expenses, including attorneys’ fees shall include any fees, costs or expenses incurred in the pursuit of any appeal and shall include any fees, costs or expenses incurred in defending any litigation or claim
brought by the Inventor regarding the provisions of this Agreement. 
 (h) Consent to Jurisdiction. The Inventor hereby
consents to the jurisdiction of the state or federal courts sitting in New Jersey over any litigation or claim brought to enforce the terms of this Agreement or to determine any rights under this Agreement. Any litigation or claim brought by the
Inventor relating in any way to this Agreement may be brought only in a state or federal court located within New Jersey. 

(i) ADVICE OF COUNSEL. THE INVENTOR ACKNOWLEDGES THAT IN EXECUTING THIS AGREEMENT THE INVENTOR HAS HAD THE OPPORTUNITY TO SEEK
THE ADVICE OF INDEPENDENT LEGAL COUNSEL, AND THE INVENTOR HAS READ AND UNDERSTOOD ALL OF THE TERMS AND PROVISIONS OF THIS AGREEMENT. THIS AGREEMENT SHALL NOT BE CONSTRUED AGAINST ANY PARTY BY REASON OF THE DRAFTING OR PREPARATION HEREOF.

 [Signature Page to Follow] 

 IN WITNESS WHEREOF, each Party has executed, or caused to be executed by a duly
authorized individual, this Agreement as of the date first set forth above. 
  

											
		 	CANCER GENETICS, INC.	 		 		 	INVENTOR
					
	By:	 	 /s/ Raju S.K. Chaganti
	 		 		 	 /s/ Louis J. Maione

		 	Name:	 	Raju S.K. Chaganti	 		 		 	Louis J. Maione
		 	Title:	 	CHAIRMAN	 		 		 	

 EXHIBIT A 

LIST OF PRIOR INVENTIONS 
 AND ORIGINAL WORKS OF AUTHORSHIP 
 EXCLUDED UNDER SECTION 3

  

					
	 Title
	  	Date	  	Identifying Number
or Brief Description
		  		  	
		  		  	

          No inventions or improvements 

         Additional Sheets Attached 

Signature of Employee:
                                         
        
 Print Name of Employee:
                                         
     
 Date:
                                         
                                     

 EXHIBIT B 

TERMINATION CERTIFICATION 
 This is to certify that I do not have in my possession, nor have I failed to return, any devices, records, data, notes, reports, proposals, lists, correspondence, specifications, drawings, blueprints,
sketches, laboratory notebooks, flow charts, materials, equipment, other documents or property, or copies or reproductions of any aforementioned items belonging to Cancer Genetics, Inc., its subsidiaries, affiliates, successors or assigns (together
the “Company”). 
 I further certify that I have complied with all the terms of the Company’s Proprietary
Information and Invention Assignment Agreement signed by me, including the reporting of any inventions and original works of authorship (as defined therein), conceived or made by me (solely or jointly with others) covered by that agreement.

 I further agree that, in compliance with the Proprietary Information and Invention Assignment Agreement, I will preserve as
confidential all trade secrets, confidential knowledge, data or other proprietary information relating to products, processes, know-how, designs, formulas, developmental or experimental work, computer programs, data bases, other original works of
authorship, customer lists, business plans, financial information or other subject matter pertaining to any business of the Company or any of its employees, clients, consultants or licensees. 

I further agree that for twelve (12) months from the date of this Certificate, I shall not either directly or indirectly solicit,
induce, recruit or encourage any of the Company’s employees or consultants to terminate their relationship with the Company, or take away, hire or otherwise engage the services of such employees or consultants, or attempt to solicit, induce,
recruit, encourage or take away, hire or otherwise engage the services of employees or consultants of the Company, either for myself or for any other person or entity. Further, for a period of twelve (12) months from the date of this
Certificate, I shall not solicit any licensor to or customer of the Company or licensee of the Company’s products, in each case, that are known to me, with respect to any business, products or services that are competitive to the products or
services offered by the Company or under development as of the date of termination of my Relationship with the Company. 
 I
further agree that for twelve (12) months from the date of this Certificate, I shall not, without the Company’s prior written consent, directly or indirectly work on any products or services that are competitive with products or services
(a) which were being commercially developed or exploited by the Company during the term of my employment relationship with the Company, and/or (b) on which I worked or about which I learned Proprietary Information (as that terms is defined
in that certain proprietary information agreement, by and between the Company and me, dated                          during my
employment relationship with the Company. 
  

					
	Date:                         	 		 	  

		 		 	Louis J. Maione

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}]]